Essential thrombocytosis secondary prevention

Essential thrombocytosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Epidemiology and Demographics
Risk Factors
Screening
Causes
Differentiating Essential thrombocytosis from other Diseases
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Essential thrombocytosis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Essential thrombocytosis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Essential thrombocytosis secondary prevention
CDC on Essential thrombocytosis secondary prevention
Essential thrombocytosis secondary prevention in the news
Blogs on Essential thrombocytosis secondary prevention
Directions to Hospitals Treating Essential thrombocytosis
Risk calculators and risk factors for Essential thrombocytosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Soujanya Thummathati, MBBS [2]

Overview

Secondary prevention strategy following essential thrombocytosis include low dose aspirin in patients at risk.

Secondary prevention

• Secondary prevention strategy following essential thrombocytosis include low dose aspirin in patients at risk. Use of aspirin may help reduce the risk of complications like:
  • Stroke
  • Myocardial infarction
  • Transient ischemic attack (TIA)

References

Template:WikiDoc Sources